US Pharma MarketingIPF biotech Celea gets $180M to follow paths of PureTech
Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
With major backing from new investors, Celea Therapeutics hopes to follow in the footsteps of its siblings Seaport Therapeutics and Karuna Therapeutics.
Celea has corralled $180 million to see if
Source: Endpoints News